Startups
Genentech and Horizon Pharma were the only two biopharma companies that made People’s 2018 list of “50 Companies That Care,” a list that highlights how a company makes a difference in the lives of its employees, as well as the communities those companies call home.
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
Shares of Eli Lilly jumped in premarket trading after the company reported total revenue of $6.35 billion for the second quarter, a 9 percent increase in revenue over the same period last year.
Since it first launched with $100 million in the bank earlier this year, Gossamer Bio has been on something of a roll.
La Jolla, California-based Human Longevity, Inc. (HLI) filed a lawsuit against the J. Craig Venter Institute (JCVI). Although Venter himself is at the center of the suit, he is not personally being sued.
Nearly four months after acquiring 100 percent control of its consumer health unit, GlaxoSmithKline Chairman Philip Hampton may be pushing for the business to become a standalone entity apart from its pharma and vaccines division, according to The Financial Times.
The Institute for Life Science Entrepreneurship (ILSE) released a white paper highlighting life science incubator space and innovation trends in New Jersey. The report, entitled “Recent Advances in Laboratory and Innovation Space in New Jersey” profiles these efforts.
This morning IFM Tre, a subsidiary of IFM Therapeutics, launched with $31 million in the bank and a focus on developing a suite of different NLRP3 antagonists.
Maryland-based Neuraly surged forth from the startup gate with $36 million in Series A funding that will finance the company’s research into the development of therapies for neurodegenerative disorders.
Fresh off its first Pipeline Day last week, Vivek Ramaswamy’s Roivant Sciences is taking aim at breaking into the Chinese market. Roivant has launched another company called Sinovant Sciences.
PRESS RELEASES